An individualized approach to tracking and treating Alzheimers disease

Clinical Pharmacology and Therapeutics

Volumn 88, Issue 4, 2010, Pages 446-449

  Rockwood, K ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; BEHAVIOR; COGNITION; COMORBIDITY; DEMENTIA; DISEASE COURSE; DISEASE SEVERITY; FUNCTIONAL ASSESSMENT; GOAL ATTAINMENT; HUMAN; MEMORY; NEUROPATHOLOGY; NOTE; PATIENT EDUCATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; SOCIAL INTERACTION; SYMPTOM; TREATMENT RESPONSE; CLINICAL TRIAL (TOPIC); METHODOLOGY; PATHOPHYSIOLOGY; PROCEDURES; TREATMENT OUTCOME;

ALZHEIMER DISEASE; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; HUMANS; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 77957050548     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.68     Document Type: Note

References (5)

1. Rockwood, K., Fay, S. & Gorman, M. The ADAS-cog and clinically meaningful change in the VISTA clinical trial of galantamine for Alzheimers disease. Int. J. Geriatr. Psychiatr. 25, 191-201 (2010).
2. Morris, J.C. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43, 2412-2414 (1993).
3. Molnar, F.J., Man-Son-Hing, M. & Fergusson D. Systematic review of measures of clinical significance employed in randomized controlled trials of drugs for dementia. J. Am. Geriatr. Soc. 57, 536-546 (2009).
4. Rockwood, K. et al. Attainment of treatment goals by people with Alzheimers disease receiving galantamine: a randomized controlled trial. CMAJ 174, 1099-1105 (2006).
5. Voss, S.E. & Bullock, R.A. Executive function: the core feature of dementia? Dement. Geriatr. Cogn. Disord. 18, 207-216 (2004).